The Recall Desk

Manufacturer

Azurity Pharmaceuticals, Inc.

4 recalls in our database name Azurity Pharmaceuticals, Inc. as the manufacturing or recalling firm.

What the numbers show

Total
4
Critical
1
Severe
1
Most recent
2024-02-07

Of the 4 recalls from Azurity Pharmaceuticals, Inc. we have scored against our rubric, 1 (25%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 1 (25%) are Severe.

About this listing

The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.

Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.

1–4 of 4

  • CriticalFDA (Drugs)·D-0323-2024·2024-02-07

    FDA Recalls Zenzedi Dextroamphetamine Sulfate Due to Label Mix-up

    The FDA has recalled Zenzedi (Dextroamphetamine Sulfate) 30 mg tablets due to a labeling error. The recall affects 4,662 bottles distributed nationwide.

    Product
    ZENZEDI — ZENZEDI (DEXTROAMPHETAMINE SULFATE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0213-2024·2024-01-10

    Prescription Oral Solution Eprontia Recalled for Out-of-Specification Impurity

    Azurity Pharmaceuticals recalls Eprontia (topiramate) oral solution nationwide because routine stability testing found an out-of-specification impurity. The chemical defect raised concerns about the drug's purity and patient safety.

    Product
    EPRONTIA — EPRONTIA (TOPIRAMATE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-0489-2023·2023-04-12

    Testosterone Cypionate Injection Recalled for Manufacturing Defect

    Azurity Pharmaceuticals is recalling Testosterone Cypionate Injection due to complaints that crystals fail to redissolve after warming and shaking, a manufacturing quality defect affecting specific lots nationwide.

    Product
    TESTOSTERONE CYPIONATE — TESTOSTERONE CYPIONATE (TESTOSTERONE CYPIONATE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-0003-2022·2021-10-13

    Firvanq Vancomycin Oral Solution Kits Recalled for Incorrect Diluent

    Azurity Pharmaceuticals is recalling 2,751 kits of Firvanq (vancomycin hydrochloride for oral solution) distributed nationwide because an incorrect diluent component was included in the kit.

    Product
    FIRVANQ — FIRVANQ (VANCOMYCIN HYDROCHLORIDE)
    Category
    Drug
    Distribution
    Distributed nationwide

About this company

Community-sourced company facts from Wikidata, not from any recall agency. This is background on the corporate entity — it says nothing about the recall(s) listed on this page, which come from the agency source notice above.

AZURITY PHARMACEUTICALS, INC.

Source: Wikidata (Q138309979), licensed CC0. Wikidata is community-edited and may not reflect the current corporate structure.